BioNexus Gene Lab Corp.
BGLC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10 | $10 | $11 | $13 |
| % Growth | -2.7% | -10.6% | -18.2% | – |
| Cost of Goods Sold | $8 | $8 | $10 | $11 |
| Gross Profit | $1 | $1 | $1 | $2 |
| % Margin | 13.6% | 13.6% | 11.5% | 16.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $2 | $2 | $2 | $1 |
| SG&A Expenses | $4 | $3 | $2 | $1 |
| Sales & Mktg Exp. | $2 | $1 | $0 | $0 |
| Other Operating Expenses | -$1 | $1 | -$0 | -$0 |
| Operating Expenses | $3 | $4 | $2 | $1 |
| Operating Income | -$2 | -$3 | -$0 | $1 |
| % Margin | -16.5% | -26.5% | -2.7% | 7.9% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$2 | -$3 | -$0 | $1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$3 | -$0 | $1 |
| % Margin | -16.8% | -26.9% | -3.3% | 5.6% |
| EPS | -0.9 | -1.53 | -0.25 | 0.53 |
| % Growth | 41.2% | -512% | -147.2% | – |
| EPS Diluted | -0.9 | -1.53 | -0.25 | 0.53 |
| Weighted Avg Shares Out | 2 | 2 | 1 | 1 |
| Weighted Avg Shares Out Dil | 2 | 2 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$2 | -$0 | $1 |
| % Margin | -14.9% | -25.4% | -1.7% | 8.7% |